| ESMO consensus guidelines for the management of patients with metastatic colorectal cancer E Van Cutsem, A Cervantes, R Adam, A Sobrero, JH Van Krieken, ... Annals of Oncology 27 (8), 1386-1422, 2016 | 1719 | 2016 |
| Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a … PM Hoff, R Ansari, G Batist, J Cox, W Kocha, M Kuperminc, J Maroun, ... Journal of Clinical Oncology 19 (8), 2282-2292, 2001 | 1415 | 2001 |
| ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making HJ Schmoll, E Van Cutsem, A Stein, V Valentini, B Glimelius, ... Annals of oncology 23 (10), 2479-2516, 2012 | 1361 | 2012 |
| Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases N Vauthey, T Pawlik, D Ribero, TT Wu, D Zorzi, P Hoff, H Xiong, C Eng, ... | 1345 | 2006 |
| Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas MA Kouvaraki, JA Ajani, P Hoff, R Wolff, DB Evans, R Lozano, JC Yao Journal of Clinical Oncology 22 (23), 4762-4771, 2004 | 651 | 2004 |
| First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous5-fluorouracil/leucovorin J Cassidy, C Twelves, E Van Cutsem, P Hoff, E Bajetta, M Boyer, R Bugat, ... Annals of oncology 13 (4), 566-575, 2002 | 573 | 2002 |
| Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines AD Yang, F Fan, ER Camp, G van Buren, W Liu, R Somcio, MJ Gray, ... Clinical cancer research 12 (14), 4147-4153, 2006 | 516 | 2006 |
| Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial A de Gramont, E Van Cutsem, HJ Schmoll, J Tabernero, S Clarke, ... The lancet oncology 13 (12), 1225-1233, 2012 | 501 | 2012 |
| Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study LB Saltz, HJ Lenz, HL Kindler, HS Hochster, S Wadler, PM Hoff, ... Journal of Clinical Oncology 25 (29), 4557-4561, 2007 | 481 | 2007 |
| Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials E Van Cutsem, PM Hoff, P Harper, RM Bukowski, D Cunningham, ... British journal of cancer 90 (6), 1190-1197, 2004 | 458 | 2004 |
| Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with … S Kopetz, PM Hoff, JS Morris, RA Wolff, C Eng, KY Glover, R Adinin, ... Journal of clinical oncology 28 (3), 453, 2010 | 457 | 2010 |
| Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alfa-2b JC Yao, A Phan, PM Hoff, HX Chen, C Charnsangavej, SCJ Yeung, ... Journal of Clinical Oncology 26 (8), 1316-1323, 2008 | 447 | 2008 |
| Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer JY Douillard, PM Hoff, JR Skillings, P Eisenberg, N Davidson, P Harper, ... Journal of Clinical Oncology 20 (17), 3605-3616, 2002 | 389 | 2002 |
| Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2–positive advanced or metastatic gastric, esophageal, or gastroesophageal … JR Hecht, YJ Bang, SK Qin, HC Chung, JM Xu, JO Park, K Jeziorski, ... Journal of Clinical Oncology 34 (5), 443-451, 2016 | 330 | 2016 |
| Improved overall survival among responders to preoperative chemoradiation for locally advanced rectal cancer NA Janjan, C Crane, BW Feig, K Cleary, R Dubrow, S Curley, JN Vauthey, ... American journal of clinical oncology 24 (2), 107-112, 2001 | 322 | 2001 |
| Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics L Claret, P Girard, PM Hoff, E Van Cutsem, KP Zuideveld, K Jorga, ... Journal of Clinical Oncology 27 (25), 4103-4108, 2009 | 240 | 2009 |
| Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer LB Saltz, HJ Lenz, H Hochster, S Wadler, P Hoff, N Kemeny, E Hollywood, ... Journal of Clinical Oncology 23 (16_suppl), 3508-3508, 2005 | 229 | 2005 |
| Long-term results using local excision after preoperative chemoradiation among selected T3 rectal cancer patients M Bonnen, C Crane, JN Vauthey, J Skibber, ME Delclos, ... International Journal of Radiation Oncology* Biology* Physics 60 (4), 1098-1105, 2004 | 226 | 2004 |
| Potential regional differences for the tolerability profiles of fluoropyrimidines DG Haller, J Cassidy, SJ Clarke, D Cunningham, E Van Cutsem, PM Hoff, ... Journal of Clinical Oncology 26 (13), 2118-2123, 2008 | 219 | 2008 |
| Carvedilol for prevention of chemotherapy-related cardiotoxicity: the CECCY trial MS Avila, SM Ayub-Ferreira, MR de Barros Wanderley, F das Dores Cruz, ... Journal of the American College of Cardiology 71 (20), 2281-2290, 2018 | 207 | 2018 |
